'김갑성' 기자의 전체기사
-
Sunsred Launches FDA-cleared Red Light Therapy Device…
SHENZHEN, China, Sept. 15, 2025 -- Shenzhen Sunsred Technology Co., Ltd. is shaking things up in the wellness tech world with its latest lineup of red light therapy devices. As a go-to OEM/ODM red light therapy manufacturer in this space, Sunsred is meeting the huge global demand for safe, effective, and certified light therapy solutions. The new range includes everything from LED face masks and flexible therapy belts to versatile light panels, all built for easy customization. This gives health, beauty, and wellness brands a strong advantage in a crowded market. Red Light Ther
- 김갑성 기자
- 2025-09-15 19:00
-
Clinically Proven Human Milk Probiotic LC40® supports Infant He…
SINGAPORE, Sept. 15, 2025 -- Supported by six clinical studies and two safety trials, Kerry's LC40® is the first probiotic strain of its kind validated for both infant and maternal applications, offering a natural, science-backed approach to early life and maternal health. Human Milk Probiotics are strains of beneficial bacteria, specifically including Lactobacillus and Bifidobacterium, naturally found in breast milk. Kerry, in collaboration with the Complutense University of Madrid, is the first to isolate these strains, including LC40® and BfM26®, using an
- 김갑성 기자
- 2025-09-15 18:20
-
Akeso Announces First Patient Dose in Global Registrational…
HONG KONG, Sept. 15, 2025 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225). The trial will evaluate cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, in combination with lenvatinib versus lenvatinib alone for the treatment of advanced hepatocellular carcinoma (HCC) in patients previously treated with atezolizumab (a PD-L1 inhibitor) and bevacizumab. COMPASSION-36 is the first global registrational Phase
- 김갑성 기자
- 2025-09-15 12:11
-
Jointly discovered KAT6i molecule originating from Australian…
[ 메디채널 김갑성 기자 ] Australian scientists who discovered how to "turn off" genes that make cancer cells grow are celebrating the next phase of development – with Pfizer's first in class KAT6 inhibitor PF-07248144 now moving to the next stages of clinical investigation. MELBOURNE, Australia, Sept. 15, 2025 -- Australian biotechnology investment and commercialisation incubator, Oncology One Pty Ltd, is pleased to report that PF-07248144, Pfizer Inc's clinical drug candidate discovered from Oncology One's out-licensed KAT6 inhibitor program, has now commenced a Phase 3 clinical tr
- 김갑성 기자
- 2025-09-15 12:06
-
New Data, iCARE Study: Hailie® Smartinhaler® Powers Unpreced…
Highlights: Up to 235% increase in real-world adherence compared to published norms (20–40%), across ~850 chronic obstructive pulmonary disease (COPD) and asthma patients. >60% patients achieved an average two-week baseline adherence with ~4 in 10 patients reaching the critical threshold of >80% adherence, a level associated with 50% fewer exacerbations and lower hospitalisations. Sustained engagement of 12+ months with 54% persistence even in high-risk, elderly patients, far above typical digital health benchmarks (30–45%). Clinically meaningful reductions in admissions,
- 김갑성 기자
- 2025-09-15 12:05
-
MGI Tech Introduces DNBSEQ-T7+: A Next-Generation 'Data Min…
SHENZHEN, China, Sept. 15, 2025 -- MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences, announced the launch of the DNBSEQ-T7+, its latest high-throughput sequencer. Designed to meet the rising demand for large-scale genomic research, the T7+ delivers more than 14 Tb/day of data in just 24 hours while offering a smaller footprint, flexible run configurations, and end-to-end automation. Internally dubbed a "data mining machine," the T7+ redefines high-throughput sequencing by combining daily output wit
- 김갑성 기자
- 2025-09-15 11:53
-
EverBridge Group and Cosmotec Forge Landmark Partnershi…
SHANGHAI, Sept. 15, 2025 -- EverBridge Group announced an Exclusive Commercialization Partnership with Cosmotec Inc. (a Wholly Owned Subsidiary of M3, Inc.; TSE: 2413) for the Japanese market. This strategic collaboration underscores EverBridge Group's leadership in proprietary R&D, stringent regulatory compliance, and value-driven ecosystem collaboration, marking a significant milestone in its global expansion strategy, further amplifying its international influence. Simultaneously, the partnership underscores Cosmotec's best-in-class digital commercialization platf
- 김갑성 기자
- 2025-09-15 08:00
-
Lion TCR Achieves Triple FDA Milestones with IND Clearance fo…
SINGAPORE and GUANGZHOU, China, Sept. 15, 2025 -- Lion TCR, a clinical-stage biotechnology company pioneering T-cell receptor (TCR)-based therapies, today announced that it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate phase1b/2 clinical trials for its proprietary TCR-T cell therapy, LioCyx-M004, in patients with chronic hepatitis B (CHB). This approval represents the third major regulatory milestone for the same product candidate, which previously received both Fast Track and Orphan Drug Designations for the treatme
- 김갑성 기자
- 2025-09-15 08:00
-
Phrontline Biopharma Announces First Patient Dosed in Pha…
SHANGHAI and SUZHOU, China, Sept. 15, 2025 -- Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the first patient has been successfully dosed in its Phase 1 clinical trial of TJ101, the company's lead asset targeting EGFR/B7-H3 with a proprietary linker-drug technology. "This is a critical milestone for Phrontline as we advance our mission to deliver innovative ADC therapies that can meaningfully impact patients' lives," said Zhaoyuan "Tony" Chen, Chief Executive Officer o
- 김갑성 기자
- 2025-09-15 08:00
-
에버브리지 그룹과 코스모텍, 랜드마크 파트너십 체결
[ 메디채널 김갑성 기자 ] 상하이, 2025년 9월 15일 -- 에버브리지 그룹(EverBridge Group)이 일본 시장 진출을 위해 코스모텍(Cosmotec Inc. TSE: 2413)과 독점 상업화 파트너십을 체결했다. 코스모텍은 M3 Inc. (도쿄 증권거래소: 2413)의 완전 소유 자회사다. 이번 전략적 협력은 에버브리지 그룹의 독자적 연구개발(R&D) 역량, 엄격한 규제 준수, 가치 중심의 생태계 협업을 보여주며 글로벌 확장 전략의 중요한 이정표가 됐다. 이를 통해 에버브리지 그룹은 국제적 영향력을 한층 강화하게 됐다. 동시에 이번 파트너십은 코스모텍의 업계 최고 수준의 디지털 상업화 플랫폼을 기반으로, 해외 의료기기의 일본 시장 진입을 가속화하고 임상 현장 사용자와의 맞춤형 소통을 지원한다. 스구루 오미나토(Suguru Ominato) 코스모텍 최고경영자(CEO)는 "에버브리지 그룹의 포트폴리오는 뛰어난 임상 효율성과 사용자 친화적인 설계를 갖추고 있어, 일본 의료진이 추구하는 첨단 치료 솔루션과 완벽히 부합한다"며 "M3의 학술 플랫폼과 코스모텍의
- 김갑성 기자
- 2025-09-15 08:00
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-10-19_SUN
- Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting 15:00
- Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia 14:00
- From Wellbeing to Academics: Why HK Parents Are Hitting Pause on Kids' Social Media and Device Use 13:00
- 내면의 조화를 발견하세요: '원더풀 인도네시아 웰니스 페스티벌 2025' 개최 01:50
- 제2회 마나르 아부다비 출품 작가 명단 공개 00:48
- 중국-피지 어업 협력, 섬나라 경제 활력 끌어올리다 00:00
2025-10-18_SAT
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 10월 19일 16시 40분